menu
    • menu
    [{"orgOrder":0,"company":"Medexus Pharmaceuticals","sponsor":"Medac","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Treosulfan","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Medexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medexus Pharmaceuticals \/ Medac","highestDevelopmentStatusID":"15","companyTruncated":"Medexus Pharmaceuticals \/ Medac"},{"orgOrder":0,"company":"Medexus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Treosulfan","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Medexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medexus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Medexus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Medexus Pharmaceuticals","sponsor":"Medac","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Treosulfan","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Medexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medexus Pharmaceuticals \/ Medac","highestDevelopmentStatusID":"15","companyTruncated":"Medexus Pharmaceuticals \/ Medac"},{"orgOrder":0,"company":"Medexus Pharmaceuticals","sponsor":"Medac","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Treosulfan","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Medexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medexus Pharmaceuticals \/ Medac","highestDevelopmentStatusID":"15","companyTruncated":"Medexus Pharmaceuticals \/ Medac"},{"orgOrder":0,"company":"Medac","sponsor":"Medexus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2021","type":"Licensing Agreement","leadProduct":"Treosulfan","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Medac","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medac \/ Medexus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Medac \/ Medexus Pharmaceuticals"},{"orgOrder":0,"company":"Medac","sponsor":"Medexus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2021","type":"Licensing Agreement","leadProduct":"Treosulfan","moa":"||DNA cross-linking","graph1":"Oncology","graph2":"Approved FDF","graph3":"Medac","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medac \/ Medexus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Medac \/ Medexus Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals for Treosulphan

    Menu

    Treosulphan

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Medexus Pharmaceuticals

                            Canada arrow
                            Interphex
                            Not Confirmed

                            Medexus Pharmaceuticals

                            Canada arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Treosulfan,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Medac

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Medexus Provides Update on Treosulfan NDA Resubmission and Provides Business Update

                            Details :

                            Product Name : Trecondyv

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            September 19, 2022

                            Lead Product(s) : Treosulfan,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Medac

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Medexus Pharmaceuticals

                            Canada arrow
                            Interphex
                            Not Confirmed

                            Medexus Pharmaceuticals

                            Canada arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Treosulfan,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Medac

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Treosulfan Pivotal Study Results Published

                            Details :

                            Product Name : Trecondyv

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            June 06, 2022

                            Lead Product(s) : Treosulfan,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Medac

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Medexus Pharmaceuticals

                            Canada arrow
                            Interphex
                            Not Confirmed

                            Medexus Pharmaceuticals

                            Canada arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Treosulfan,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Medac

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Medexus Pharmaceuticals Provides Update on Resubmission of Treosulfan NDA

                            Details :

                            Product Name : Trecondyv

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            May 25, 2022

                            Lead Product(s) : Treosulfan,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Medac

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Medexus Pharmaceuticals

                            Canada arrow
                            Interphex
                            Not Confirmed

                            Medexus Pharmaceuticals

                            Canada arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Treosulfan,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Medexus Pharmaceuticals Announces Resubmission of Treosulfan NDA

                            Details :

                            Product Name : Trecondyv

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            April 22, 2022

                            Lead Product(s) : Treosulfan,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Medac

                            Germany arrow
                            Interphex
                            Not Confirmed

                            Medac

                            Germany arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Treosulfan,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Medexus Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Medexus Pharmaceuticals and medac GmbH enter into Licensing Agreement for First-in-Class Conditioning Agent, T...

                            Details : Treosulfan will be marketed in Canada under the brand name Trecondyv® and indicated in combination with fludarabine as part of a conditioning treatment prior to allogeneic hematopoietic stem cell transplantation (“allo-HSCT”).

                            Product Name : Trecondyv

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            December 07, 2021

                            Lead Product(s) : Treosulfan,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Medexus Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Medac

                            Germany arrow
                            Interphex
                            Not Confirmed

                            Medac

                            Germany arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Treosulfan,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Medexus Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Medexus and Medac Enter Into a License Agreement for Treosulfan, in the United States

                            Details : Medac intends to leverage its strong, existing commercial infrastructure in the United States to address the underserved allo-HSCT market through its commercialization of treosulfan.

                            Product Name : Trecondyv

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            February 02, 2021

                            Lead Product(s) : Treosulfan,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Medexus Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth